The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment - A pilot study
The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment - A pilot study
复制标题
DOI：
10.1002/cncr.21667
复制
发表时间：
2006-02-15
期刊：
影响因子：
6.2
通讯作者：
Yamamoto, K
中科院分区：
文献类型：
--
作者：
Mizuta, T;Ozaki, I;Yamamoto, K
背景肝细胞癌（HCC）的高复发率决定了HCC患者的长期预后。在目前的研究中，作者测试了维生素K2类似物menatetrenone对肝癌复发和治愈性治疗后生存率的影响。将61例在手术切除或经皮局部消融后诊断为无HCC的患者随机分配到甲烯雌酮组（n = 32例患者）或对照组（n = 29例患者）。在menatetrenone组的患者接受每日口服剂量为45毫克的menatetrenone。分析HCC患者的疾病复发率和生存率。在12个月、24个月和36个月时，甲烯雌酮组的累积复发率分别为12.5%、39.0%和64.3%;对照组的相应复发率分别为55.2%、83.2%和91.6%（P 0.0002）。即使对于血清脱-γ-羧基-凝血酶原基线水平较低的患者也获得了类似的结果。单变量和多变量考克斯比例风险分析表明，甲烯雌酮的使用是与肝癌复发率相关的唯一因素。接受甲那孕酮治疗的患者12个月、24个月和36个月的累积生存率分别为100%、96.6%和87.0%;对照组患者的相应生存率分别为96.4%、80.9%和64.0%（P = 0.051）。目前的研究结果表明，menatetrenone可能具有抑制HCC复发的作用，并对生存率有有益的影响，尽管需要更大的安慰剂对照试验来证明这些作用。
BACKGROUND. The high recurrence rate of hepatocellular carcinoma (HCC) determines the long-term prognosis for patients with HCC. In the Current study, the authors tested the effects of menatetrenone, a vitamin K2 analog, on recurrent HCC and survival after curative treatment.METHODS. Sixty-one patients who were diagnosed as free of HCC after Surgical resection or percutaneous local ablation were assigned randomly assigned to either a menatetrenone group (n = 32 patients) or a control group (n = 29 patients). Patients in the menatetrenone group received a daily oral dose of 45 mg of menatetrenone. Disease recurrence and survival rates were analyzed in patients with HCC.RESULTS. The cumulative recurrence rates in the menatetrenone group were 12.5% at 12 months, 39.0% at 24 months, and 64.3% at 36 months; and the corresponding recurrence rates in the control group were 55.2%, 83.2%, and 91.6%, respectively (P 0.0002). Similar results were obtained even for patients who had low baseline levels of serum des-gamma-carboxy-prothrombin. Univariate and multivariate Cox proportional hazard analyses showed that the administration of menatetrenone was the only factor related to the recurrence rate of HCC. The cumulative Survival rates for the patients who received menatetrenone were 100% at 12 months, 96.6% at 24 months, and 87.0% at 36 months; and the corresponding survival rates for patients in the control group were 96.4%, 80.9%, and 64.0%, respectively (P = 0.051).CONCLUSIONS. The current study findings suggested that menatetrenone may have a Suppressive effect oil recurrence of HCC and a beneficial effect on Survival although a larger, placebo-controlled trial will be required to prove these effects.